The review found no eligible studies for this question.
The review found no eligible studies for this question.
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
Posterior reconstruction showed no clear difference in serious adverse events compared with no posterior reconstruction (moderate certainty).
It is very uncertain whether retzius‐sparing RALP changes serious adverse events compared with standard RALP (very low certainty).
Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).
It is very uncertain whether antimicrobial changes serious adverse events compared with placebo or no antibiotics (very low certainty).
It is very uncertain whether scheduled PDE5I changes serious adverse events compared with on demand PDE5I (very low certainty).
Scheduled PDE5I may leads to lower serious adverse events compared with on demand placebo or no treatment (low certainty).
It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
The review found no eligible studies for this question.
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).